Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous HCV Non Responders ANRSHC03 BITRI

NCT00122629 is registered in ClinicalTrials.gov with French National Agency for Research on AIDS and Viral Hepatitis as lead sponsor.

NCT NCT00122629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00122629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous HCV Non Responders ANRSHC03 BITRI
Lead sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2000
Completion date
May 31, 2003
Enrollment
405
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic